Personalis-Tempus AI deal clears US antitrust waiting period under HSR Act
Bitget2026/10/06 20:07Tempus AI agreed to acquire Personalis through a two-step merger, leaving Personalis as an indirect wholly owned Tempus unit. The antitrust waiting period for the deal expired at 11:59 p.m. ET on Oct. 2, 2026. Tempus withdrew its initial filing on Aug. 31, 2026, then refiled on Sept. 2, 2026, restarting the 30-day clock. Closing now hinges on Personalis shareholder approval at a virtual meeting, with the date still to be set. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Personalis Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-415547), on October 06, 2026, and is solely responsible for the information contained therein.
- Tempus AI agreed to acquire Personalis through a two-step merger, leaving Personalis as an indirect wholly owned Tempus unit.
- The antitrust waiting period for the deal expired at 11:59 p.m. ET on Oct. 2, 2026.
- Tempus withdrew its initial filing on Aug. 31, 2026, then refiled on Sept. 2, 2026, restarting the 30-day clock.
- Closing now hinges on Personalis shareholder approval at a virtual meeting, with the date still to be set.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Caribou shares plunge as company explores sale and cancels cancer project
October 7 - ** Caribou Biosciences (CRBU.O) shares fell 35.9% in pre-market trading to $0.72 ** Caribou Biosciences announced late Tuesday that it is exploring strategic options, including a potential sale, merger, or other transactions, to maximize shareholder value ** Caribou said it plans to halt development of its allogeneic CAR-T cell therapy programs, including vispa-cel for non-Hodgkin lymphoma and CB-011 for multiple myeloma ** Caribou also stated it will lay off employees and cut costs, with most layoffs expected to be completed by Q4 2026 ** As of June 30, the company held $113.8 millions in cash, cash equivalents, and marketable securities ** As of the previous trading day's close, the company's share price had dropped about 28% year-to-date (Note: For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them only for reader convenience. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation features.)
Australian Dollar: Neutral outlook inside tight range against US Dollar – UOB
Power Root buys back shares for MYR 147,891.13
Power Root bought back 134,300 ordinary shares on Oct. 7, 2026, paying MYR 147,891.13. Purchases were priced between MYR 1.08 and MYR 1.12; all shares were retained as treasury stock. Treasury shares rose to 16,051,800, representing 3.78% of issued shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Power Root Bhd published the original content used to generate this news brief via Bursa Malaysia (KLSE) (Ref. ID: 3712895) on October 07, 2026, and is solely responsible for the information contained therein.
Crypto prices
More
